Valuation: EyePoint, Inc.

Market Cap 3.01Cr 2.74Cr 2.54Cr 2.29Cr 4.3Cr 280.76Cr 4.5Cr 31Cr 12Cr 151.71Cr 11Cr 11Cr 480.58Cr P/E 2026 *
-0.07x
P/E 2027 * -0.16x
Enterprise Value -11Cr -10Cr -9.27Cr -8.39Cr -16Cr -1.03TCr -16Cr -112.09Cr -44Cr -554.88Cr -41Cr -40Cr -1.76TCr EV / Sales 2026 *
-54.7x
EV / Sales 2027 * -221x
Free-Float
97.33%
Yield 2026 *
-
Yield 2027 * -
1 day-2.87%
1 week-17.31%
Current month-24.17%
1 month-39.95%
3 months-95.81%
6 months-97.76%
Current year-98.55%
1 week 0.26
Extreme 0.2639
0.32
1 month 0.26
Extreme 0.2639
0.44
Current year 0.26
Extreme 0.2639
18.87
1 year 0.26
Extreme 0.2639
19.11
3 years 0.26
Extreme 0.2639
30.99
5 years 0.26
Extreme 0.2639
30.99
10 years 0.26
Extreme 0.2639
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-1,39,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-2.87%-17.31%-98.15%-96.03% 3.09Cr
-2.29%-5.34%+28.73%+128.34% 1,23200Cr
-2.04%-5.78%+31.91%+78.34% 66TCr
-0.86%-3.71%+21.74%+105.02% 51TCr
-1.04%-1.80%+28.69%+68.01% 38TCr
-3.61%-9.62%+39.73%+30.53% 34TCr
-3.22%-5.20%+24.48%+51.30% 29TCr
-2.51%-4.49%-2.15%+29.67% 28TCr
-1.14%-6.05%+28.16%+65.35% 24TCr
-1.45%-0.85%+30.03%+120.72% 21TCr
Average -2.10%-4.44%+13.32%+58.12% 41TCr
Weighted average by Cap. -2.04%-2.67%+26.93%+87.80%

Financials

2026 *2027 *
Net sales 20.09L 18.31L 16.95L 15.33L 28.76L 19Cr 30.1L 2.05Cr 81.26L 10Cr 75.39L 73.81L 32Cr 9L 8L 8L 7L 13.14L 8.57Cr 13.75L 93.59L 37.13L 4.63Cr 34.44L 33.72L 15Cr
Net income -34Cr -31Cr -28Cr -26Cr -48Cr -3.15TCr -51Cr -344.1Cr -136.5Cr -1.7TCr -126.63Cr -123.98Cr -5.4TCr -19Cr -18Cr -16Cr -15Cr -28Cr -1.82TCr -29Cr -198.49Cr -79Cr -982.62Cr -73Cr -72Cr -3.11TCr
Net Debt -14Cr -13Cr -12Cr -11Cr -20Cr -1.31TCr -21Cr -142.74Cr -57Cr -706.59Cr -53Cr -51Cr -2.24TCr -23Cr -21Cr -20Cr -18Cr -33Cr -2.18TCr -35Cr -237.63Cr -94Cr -1.18TCr -87Cr -86Cr -3.73TCr
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
19/26/19 $0.2642 -2.87% 34,46,903
18/26/18 $0.2720 -8.08% 36,10,328
17/26/17 $0.2959 -3.80% 45,76,326
16/26/16 $0.3076 +0.52% 65,46,986
13/26/13 $0.3060 -4.23% 30,86,415
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.2642USD
Average target price
8.312USD
Spread / Average Target
+3,046.29%
  1. Stock Market
  2. Stocks
  3. EYPT Stock